FDA DELAYS GENERIC COMPETITION FOR TOP SALIX DRUG

Salix Pharmaceuticals has secured six more months of market protection from generic competition for its most lucrative drug. The Raleigh biotech said Monday that the U.S. Food and Drug Administration has granted the company an extension of market exclusivity for Colazal, which is used to fight inflammation of the large intestine in children ages 5 through 17.
Triangle Business Journal